C. Mapagu

Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor–Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer

A. deFazio, P. Beale, M. Friedlander, 2017, International Journal of Gynecologic Cancer.

Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma

A. deFazio, P. Beale, R. Balleine, 2023, Translational oncology.

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

A. deFazio, P. Beale, F. Amant, 2019, Journal of gynecologic oncology.

Epithelial ovarian cancer: Genomic landscape and evolving precision treatment

A. deFazio, P. Harnett, B. Gao, 2021, Overcoming Ovarian Cancer Chemoresistance.

Clinical and molecular profile of young adults with early‐onset colorectal cancer: Experience from four Australian tertiary centers

N. Pavlakis, L. Chantrill, D. Goldstein, 2022, Asia-Pacific journal of clinical oncology.

Intermittent intussusception

C. Mapagu, D. Fitzgerald, Hco Martin, 2003, Journal of paediatrics and child health.

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.

N. Traficante, S. Fereday, A. deFazio, 2018, Gynecologic oncology.